The discovery was made in the laboratory of Sachdev Sidhu, PhD., a professor of Molecular Genetics at the University of Toronto's Donnelly Centre for Cellular and Biomolecular Research and founder of the Toronto Recombinant Antibody Centre.
The speed and scale of the COVID-19 pandemic has revealed the urgent need for better methods for developing and testing novel therapeutics. The crisis has presented severe challenges to global health but has also provided an opportunity to integrate advanced methods.
The founders of Virna Therapeutics include Dr. Sachdev Sidhu (chief scientific officer), leader of the discovery and development process, Suresh K. Jain, PhD. (president and chief executive officer), a
Boston-based serial biotech entrepreneur with a track record of success in building world-class organizations and teams, and Pier Paolo Pandolfi, MD., PhD., FRCP, a famed cancer molecular geneticist and RNA therapy expert.
Virna Therapeutics has a three-pronged strategy to target the COVID-19 virus: neutralizing antibodies that will prevent the virus from entering host cells, CRISPR/Cas13d-based and LNA-based technologies for the treatment and prevention of RNA virus infection and novel protease inhibitors that will prevent replication and release from host cells.
Founded in 1827, the University of Toronto includes the Donnelly Centre, a research institute where scientists from diverse fields make discoveries to improve health.
It houses the Toronto Recombinant Antibody Centre, which produces a variety of antibodies to support academic collaborations, industry partnerships and to help seed promising start-up companies.
U of T's Innovations and Partnership Office is responsible for the negotiation and licensing of biologics from the university and represents U of T in its commercial transactions with VIRNA.
Virna Therapeutics Inc. is a privately held biotech company specialising in multi-pronged discovery technologies.
While Virna is researching multiple approaches for treating infectious diseases, their validated synthetic antibody technology is a powerful platform enabling efficient generation of fully-human monoclonal antibodies.
The company is headquartered in Boston, Massachusetts and has a registered office in Montreal.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients